CEO Ryan Fukushima stresses that Lens consolidates complex real-world data workflows into a single platform to accelerate development paths and improve decision-making.

Tempus issues forward-looking risk disclosures about uncertainties in product impact, market adoption, regulatory compliance, competition, IP protection, and other factors, with updates only as required by law.

Tempus AI unveils the next generation of Lens, its agentic platform for oncology drug development, designed to speed research and decision-making in biopharma.

Lens is gaining rapid adoption, already used by 19 of the top 20 largest biopharma companies.

The platform supports auditability and extension by exporting projects to private Workspaces and providing a code view for validation.

Readers can find more information and access Lens at lens.tempus.ai.

While pricing and broader availability aren’t disclosed, Lens is commercially available at lens.tempus.ai and is marketed for rapid insight generation in minutes.

Key features include: (1) Custom Research Plan Generation by Lens Co-scientist agents from plain-language hypotheses; (2) On-Demand Execution against Tempus’ library of over 8.5 million de-identified patient records; (3) Specialized AI Agents for use cases like biomarker validation and trial design; (4) Reproducible Intelligence with interactive reports, audit-friendly code views, and exportable private workspaces.

Lens offers co-scientist support via Tempus One, end-to-end workflow consolidation, and the ability to export projects to private workspaces for extension and transparency.

The platform delivers a multi-agent, end-to-end experience with plan generation, on-demand data execution, specialized agents, and reproducible intelligence with transferable code views.

Tempus’ broader mission is to apply AI to precision medicine, leveraging one of the world’s largest multimodal data libraries to support patient care and therapeutic discovery.

The press release includes standard forward-looking statements and risk disclosures, and provides media contact information.